30-day average of 18 articles · scale −100 to +100
Across 18 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Bristol-Myers Squibb Company news is Somewhat Bullish (+40)
on a scale from −100 to +100.
That is up 10 points from the previous 30 days (+30).
📈 BMY stock returned 40.5% over three years, trading near $62.91.
💰 Company generated $9.3 billion in free cash flow last twelve months.
Slightly Bullish +15
Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% ...
AI-generated analysis
Key insights
📈 BMY stock has returned approximately 40.5% over the past three years, trading near $62.91 per share.
💰 The company generated about $9.3 billion in free cash flow over the last twelve months according to the analysis.
🔬 Recent positive data for Camzyos and new approvals for ZENBEXUS are expected to support future drug-driven cash flows.
⚠️ Investors face a projected revenue step-down from Eliquis beginning in 2027 as part of the company's lifecycle management.
💡 A bullish narrative suggests BMY is 21% undervalued if late-stage platforms like CAR-T and ADCs succeed commercially.
📉 A bearish perspective argues the stock is 121% overvalued at current levels, with price being the primary sticking point.
💸 The company has implemented a plan to generate $2 billion in cost savings to offset revenue shifts.
🧠 Simply Wall St analysis indicates the fair value depends on successfully converting late-stage platforms into meaningful products.
📈 Bullish signals
🔬Recent trial results for Camzyos and new product approvals for ZENBEXUS are expected to support expectations for future drug-driven cash flows.
💡The company has a solid pipeline story with late-stage platforms in areas like CELMoDs, CAR-T, ADCs, Factor XI inhibition, and neuroscience that could convert into commercially meaningful products.
💡A bullish analyst narrative suggests the stock is 21% undervalued if the company successfully manages revenue transitions from legacy assets like Eliquis.
📉 Risk factors
💰The DCF model assumes a gently declining free cash flow pattern over the next decade as major products mature and new launches fill gaps only gradually.
📉A bearish investor narrative argues the stock is 121% overvalued at current levels, stating that the entry price exceeds fair value filters despite the company's quality.
⚠️The analysis projects a step-down in revenue from Eliquis starting in 2027, which constrains growth assumptions in the valuation model.
Article
Bristol-Myers Squibb (BMY) shares have appreciated approximately 40.5% over the past three years, trading around $62.91 per share. The article analyzes whether this valuation is justified by the company's long-term cash flow generation capabilities, utilizing a Discounted Cash Flow (DCF) model that projects free cash flow of roughly $9.3 billion over the last twelve months.
The analysis suggests BMY may be undervalued based on intrinsic value calculations derived from its cash flow profile. Key drivers supporting this view include recent positive trial results for Camzyos and new product approvals for ZENBEXUS, which are expected to bolster future drug-driven cash flows despite anticipated revenue declines from the legacy asset Eliquis starting in 2027.
Simply Wall St presents a split narrative regarding BMY's fair value. A bullish perspective argues the stock is 21% undervalued if the company successfully commercializes its late-stage platforms in areas like CAR-T and ADCs while managing revenue transitions. Conversely, a bearish view contends the stock is 121% overvalued at current levels, citing that the entry price exceeds fair value filters despite the underlying quality of the business.
The article concludes by emphasizing the importance of leadership strategy in shaping BMY's future trajectory. It notes that while the company has a solid pipeline and cost-saving plans totaling $2 billion, investors must weigh these factors against the specific assumptions regarding growth margins and earnings required to justify the current market price.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Published on May 2, 2026, this article argues that Bristol-Myers Squibb Company (BMY) is currently undervalued by the market despite facing a significant patent cliff in 2026. The stock is trading at a discounted forward price-to-earnings ratio of 9.4x, a valuation driven largely by investor fears regarding expiring patents. However, the author contends that the company is robustly equipped to navigate this challenge with a strong pipeline and substantial CAR-T optionality that remains largely unpriced in the current valuation model. Underlying these risks are compelling fundamentals, including a 15-20% base case upside potential combined with a 4.3% dividend yield.
The near-term catalyst stack for BMY in 2026 includes several key compounds: Milvexian, Iberdomide, Cobenfy, and Sotyktu. The article suggests that the success of any one of these assets could trigger a significant rerating of the stock, pushing its forward P/E multiple from current levels to a range of 10x-11x. Beyond these immediate drivers, BMY's advanced CAR-T program, particularly zola-cel targeted for autoimmune indications, is highlighted as a major source of long-term optionality that offers further upside potential beyond the current market consensus.
The author of the piece, Joseph "Kade" Minton, identifies himself as an engineering physics and applied mathematics graduate who now works in environmental and industrial compliance. He utilizes quantitative models incorporating concepts such as differential equations and linear algebra, while balancing them with macroeconomic winds and historical regulatory precedent to identify speculative growth stocks he believes are undervalued. His broader thesis posits that the biotech sector is approaching a golden era characterized by revolutionary breakthroughs in treating diseases like cancer, Alzheimer's, and autoimmune disorders, alongside advancements in technology such as fusion energy and solid-state batteries.
The author discloses holding beneficial long positions in shares of KYTX, RNAC, CABA, and CRBU, though he states he does not hold a business relationship with any company mentioned in the text except for those specific holdings or through Seeking Alpha. Seeking Alpha's standard disclaimers note that past performance does not guarantee future results and that the article expresses the author's own opinions rather than the views of the platform as an investment advisor. The content explicitly avoids giving recommendations or advice on investment suitability for any particular investor.
📉 BMY trades at 9.4x P/E, offering 15-20% upside toward a 10x-11x multiple.
💊 Robust CAR-T pipelines and new drugs provide strong growth catalysts by 2026.
💹 Attractive 4.3% dividend yield adds value to this undervalued investment target.
📉 Bristol-Myers Squibb (BMY) stock currently trades at a low 9.4x forward P/E ratio, driven primarily by market concerns over an upcoming patent cliff.
💊 The company is considered well-equipped with a robust pipeline and significant CAR-T therapy optionality to navigate potential challenges.
📈 Investors could see 15-20% base case upside if the stock re-rates toward a 10x-11x forward P/E multiple based on new catalysts.
💹 BMY offers an attractive 4.3% dividend yield, adding to its potential as an undervalued investment target.
🚀 Key 2026 drug catalysts include Milvexian, Iberdomide, Cobenfy, and Sotyktu, which are expected to drive growth in specific indications.
🔬 The company's advanced CAR-T program features zola-cel targeting autoimmune diseases, representing a long-term growth avenue not yet fully priced into the valuation.
📝 The article author, Joseph "Kade" Minton, is an engineering physics background investor who focuses on speculative growth stocks in biotech and tech sectors.
🤖 The author posits that the biotech sector is entering a golden era with breakthroughs in cancer, Alzheimer's, and autoimmune disorder treatments.
⚠️ The analysis highlights that while patent expiration fears are prevalent, the market has significantly underpriced BMY's potential value.
🔍 The article serves as an investment thesis suggesting BMY is undervalued despite traditional risks associated with biotech patents expiring.
Bullish Signals
Bristol-Myers Squibb (BMY) trades at a discounted 9.4x forward P/E, presenting a compelling entry point with an estimated 15-20% base case upside.
The company offers a generous 4.3% dividend yield, providing downside protection and income potential for investors.
A strong pipeline of catalysts including Milvexian, Iberdomide, Cobenfy, and Sotyktu is positioned to drive a potential valuation rerating to 10x-11x forward P/E.
The advanced CAR-T program, specifically zola-cel for autoimmune diseases, provides long-term optionality that remains largely unpriced into the current stock valuation.
Despite fears of a patent cliff, management is well-equipped with a robust pipeline and significant strategic assets to sustain future growth.
Risk Factors
Bristol-Myers Squibb faces a 'major patent cliff', with multiple patents expiring within a short timeframe, which is the primary reason the stock trades at a discounted 9.4x forward P/E.
The current valuation of 9.4x forward P/E reflects significant market fears regarding revenue decline due to patent expirations.
Bristol-Myers Squibb (BMY) shares are trading at $58.30, reflecting a decline of $2.29 or 3.78% as of May 1, 2026. The company is currently on pace for its largest percentage decrease since November 14, 2025, when the stock fell 4.07%. This latest drop marks the fourth consecutive day of losses for the stock and contributes to a week characterized by poor performance, with shares down 0.70%. Notably, this weekly decline represents the worst performance since the week ending April 24, 2026, when BMY fell 2.43%.
In terms of longer-term trends, Bristol-Myers Squibb's current price is down 28.14% from its all-time closing high of $81.13 on December 2, 2022. Despite the recent decline, the stock remains up 15.29% from its closing price one year ago, which was $50.57 on May 2, 2025. The shares are also down 6.53% from its 52-week closing high of $62.37 set on February 27, 2026, but remain up 36.85% from its 52-week low of $42.60 reached on October 29, 2025. The intraday trading saw shares drop an additional 4.23% at their lowest point today, marking the largest single-day intraday decrease since April 2, 2026. Consequently, BMY ranks as the fifth worst performer within the S&P 500 for the day.
📉 BMY shares fell 3.78% in their worst weekly session since April 2026.
⏳ Stock is down roughly 28% from its 2022 all-time high.
⚠️ It ranks as the fifth-worst performer in the S&P 500 today.
📉 Bristol-Myers Squibb (BMY) shares fell 3.78% to $58.30, marking the largest percentage decrease since November 2025.
⏳ The stock is currently down for four of the past six trading sessions.
📅 This week represents BMY's worst weekly performance since late April 2026 when it fell 2.43%.
📉 Shares are down approximately 28% from their all-time closing high reached in December 2022.
⬆️ Despite recent weakness, the stock remains up over 15% compared to its price a year ago.
⬇️ The current price sits below its 52-week high of $62.37 and above its 52-week low of $42.60.
⚠️ Intraday drops hit 4.23%, the largest percentage decline observed since April 2026.
🏆 BMY was among the worst performers in the S&P 500 today, ranking fifth on the list.
📰 The data report originates from Dow Jones and is timestamped May 1, 2026.
⚠️ Morningstar includes a standard disclaimer that third-party content is not verified or endorsed.
❗ Investors are advised to seek independent financial advice before making decisions based on this market data.
🎯 The report concludes coverage of the markets and weekly wrap-up topics including energy stocks and IPO questions.
Bullish Signals
The stock remains up 15.29% from 52 weeks ago (May 2, 2025), when it closed at $50.57, demonstrating long-term value.
Bristol-Myers Squibb is up 36.85% from its 52-week closing low of $42.60 on Oct. 29, 2025, indicating significant recovery potential.
Risk Factors
Bristol-Myers Squibb (BMY) is currently at $58.30, marking a 28.14% decline from its all-time high of $81.13 reached on Dec. 2, 2022.
The stock is down 6.53% from its 52-week closing high of $62.37 recorded on Feb. 27, 2026, indicating sustained pressure below recent peaks.
BMY has been down four of the past six trading days, with the current intraday drop of 4.23% being the largest since April 2, 2026.
The stock ranks as the fifth worst performer in the S&P 500 for the current session, highlighting significant relative weakness compared to peers.
This price decline follows the company's status as being on pace for its largest percent decrease since November 14, 2025.
Bristol Myers Squibb reported solid first-quarter results with total revenue of approximately $11.5 billion, representing a 1% year-over-year increase, while its growth portfolio expanded by 9% to reach $6.2 billion. Key performers included Breyanzi, which grew 53%, and Camzyos, whose revenue nearly doubled to $314 million driven by global demand. However, Opdivo revenue decreased 8% to about $2.1 billion due to a U.S. wholesaler inventory drawdown, while Eliquis revenue rose 13% to $4.1 billion despite a U.S. price reduction that impacted collections. Other notable growth came from Reblozyl (up 15%), Sotyktu (up 20% globally), and Cobenfy ($56 million in revenue).
Gross margin declined by 280 basis points to 70.3% primarily due to product mix, while diluted EPS stood at $1.58, which included a net $0.03 per-share charge related to in-process R&D. The company ended March with approximately $11 billion in cash and marketable securities, generating roughly $1.1 billion in operating cash flow, though this was affected by about $1.2 billion in lower net cash collections from Eliquis price reductions. Chief Executive Officer Chris Boerner emphasized improved execution, stating the company is delivering a solid Q1 and maintaining shareholder-friendly capital allocation, while CFO David Elkins noted that results are trending toward the upper end of full-year 2026 guidance.
The pipeline remains a strategic focus with multiple pivotal readouts expected in late 2026 for milvexian, Cobenfy, admilparant, and iberdomide. The FDA accepted iberdomide for relapsed/refractory multiple myeloma with breakthrough therapy designation and priority review, setting a PDUFA date of August 17. Additionally, the company reported positive interim data for mezigdomide from the SUCCESSOR-2 study, showing meaningful improvement in progression-free survival, and shared positive top-line results for the antibody-drug conjugate iza-bren in a China study treating triple-negative breast cancer. The company is also pursuing $2 billion in productivity savings by end-2027 while remaining selective on business development initiatives.
📈 Q1 revenue rose 1% to $11.5B, with growth portfolio up 9% driven by new products.
💊 Key drugs Breyanzi and Camzyos surged, though Opdivo dropped due to inventory drawdowns.
💰 Company holds $11B cash, reaffirmed 2026 guidance, and pursues $2B in productivity savings.
📈 Bristol Myers Squibb reported first-quarter total revenue of approximately $11.5 billion, representing a 1% year-over-year increase.
🚀 Growth portfolio revenue reached $6.2 billion, up 9% as new products drove expansion in the business.
💊 Breyanzi sales surged 53%, while Camzyos revenue nearly doubled to $314 million amid strong global demand.
⬇️ Opdivo revenue declined 8% to $2.1 billion due to a temporary U.S. wholesaler inventory drawdown.
💉 Eliquis revenue rose 13% to $4.1 billion despite a price reduction and expected inventory normalization in Q2.
🔬 The FDA accepted the iberdomide application for multiple myeloma with priority review, targeting an August 17 decision.
🧬 Positive interim data were reported for mezigdomide showing meaningful improvement in progression-free survival.
⚖️ Gross margin declined by 280 basis points to 70.3% primarily due to product mix and lower collections from price reductions.
💰 The company ended the quarter with $11 billion in cash and equivalents while generating $1.1 billion in operating cash flow.
📉 Diluted EPS came in at $1.58, which included a net charge related to in-process R&D and licensing income.
🎯 Management reaffirmed full-year 2026 guidance and noted results are trending toward the upper end of established ranges.
💸 The company is pursuing approximately $2 billion in productivity savings by the end of 2027 through strategic initiatives.
📊 Opdualag continued to post double-digit growth, while Sotyktu increased 20% globally following a new approval.
🔗 Additional revenue came from Qvantig ($163M), Cobenfy ($56M), and Reblozyl (which grew 15%).
👨💼 CEO Chris Boerner emphasized disciplined execution and improving the company's "say-do ratio" across operations.
🗓️ Late 2026 is identified as a key period for multiple pivotal readouts including milvexian and new ADC data.
Bullish Signals
Bristol Myers Squibb delivered solid Q1 results with total revenue of approximately $11.5 billion, marking a 1% year-over-year increase.
The growth portfolio increased by 9% to $6.2 billion, demonstrating strong momentum in high-potential product lines.
Breyanzi revenue grew 53%, attributed to its best-in-class profile and demand across approved indications in the U.S. and international markets.
Camzyos revenue nearly doubled to $314 million, driven by continued global demand for the heart condition treatment.
Eliquis revenue increased 13% to approximately $4.1 billion, reflecting strong underlying demand despite recent price reductions.
Reblozyl grew 15%, showing continued uptake in first- and second-line treatments for MDS-associated anemia.
Sotyktu achieved a 20% global growth rate following its recent approval in psoriatic arthritis, with positive potential in lupus and Sjögren's disease pipelines.
Opdualag posted another quarter of double-digit growth, reinforced by global demand and its status as the standard of care in first-line melanoma treatment.
The company secured major regulatory milestones, including FDA acceptance of iberdomide for multiple myeloma with breakthrough therapy designation and a PDUFA date of Aug. 17.
Management highlighted positive phase III interim data for mezigdomide, which demonstrated meaningful improvement in progression-free survival.
Bristol Myers Squibb reaffirmed its full-year 2026 guidance, tracking toward the upper end of established ranges, signaling management confidence.
The company ended March with a robust $11 billion in cash equivalents and marketable securities while maintaining disciplined capital allocation.
Risk Factors
Opdivo revenue declined 8% to $2.1 billion, driven by a U.S. wholesaler inventory drawdown with levels at the low end of the typical range.
Eliquis collections were negatively impacted by a U.S. price reduction implemented at the start of the year and increased generic entry across several other brands.
Gross margins contracted 280 basis points to 70.3%, primarily due to product mix shifts rather than operational efficiency gains.
Operating expenses rose slightly above the prior-year period at $3.9 billion, partly due to incremental investments in new drug candidates.
The company recorded a net $0.03 per-share charge related to in-process R&D and licensing income which impacted diluted EPS of $1.58.
Cash collections were down approximately $1.2 billion quarter-over-quarter tied to the Eliquis list price reductions, creating near-term headwinds for cash flow.
Management reaffirmed full-year 2026 guidance while pursuing productivity savings, indicating ongoing pressure to manage costs and margins amidst growth investments.
Bristol Myers Squibb (BMY) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong growth in key pharmaceuticals like Eliquis and newer cancer therapies. The company posted adjusted earnings of $1.58 per share, surpassing the analyst consensus of $1.42, while revenue reached $11.49 billion against a forecast of approximately $10.9 billion. Shares rose 4% following the announcement. Eliquis, sold in partnership with Pfizer, contributed $4.14 billion to quarterly sales, reflecting a 16% year-over-year increase and maintaining over 75% of the new prescription share, indicating sustained demand. Growth from newer medicines, including cell therapies like Breyanzi and Camzyos, helped offset declines in older products such as Revlimid, which has faced generic competition. The revenue from this growth portfolio increased 12% to $6.23 billion, representing more than half of total revenue.
Despite the overall beat, some analysts noted mixed performance in specific areas. RBC Capital Markets analyst Trung Huynh pointed out that while the quarterly result was positive, the long-term outlook relies more on catalysts expected in the second half of 2026, such as approvals for next-generation cancer drugs and late-stage study results for milvexian and Cobenfy. Additionally, Opdivo sales dropped 5% to $2.15 billion, missing estimates of $2.33 billion, which finance chief David Elkins attributed to wholesalers reducing inventory levels, a situation the company is monitoring closely. The company also recorded $163 million in sales for its recently launched subcutaneous version, Opdivo Qvantig.
Looking forward, Bristol Myers Squibb reaffirmed its full-year 2026 outlook with projected revenue between $46.0 billion and $47.5 billion and adjusted earnings per share ranging from $6.05 to $6.35, expecting results to trend toward the higher end of these ranges. CEO Chris Boerner highlighted strategic initiatives, including expanding artificial intelligence usage in research and development to identify potential drug molecules 50% faster and reduce clinical development cycle times by 30%. Ongoing cost-cutting efforts have already yielded $1 billion from a planned $2 billion savings target by the end of 2025, with the full amount expected by the end of next year. These savings are intended to support investment in new medicines and dividend growth.
📈 Q1 adjusted earnings of $1.58 beat estimates, driving shares up 4%.
💰 Revenue hit $11.49 billion with Eliquis sales rising 16%.
🚀 Growth portfolio and AI adoption continue to drive innovation and efficiency.
📈 Bristol Myers Squibb reported Q1 adjusted earnings of $1.58 per share, beating the analyst average expectation of $1.42.
💰 Revenue came in at $11.49 billion, surpassing expectations of approximately $10.9 billion and driving shares up 4%.
💉 Sales of Eliquis reached $4.14 billion, a 16% increase year-over-year with new prescription share exceeding 75%.
🚀 Growth portfolio sales rose 12% to $6.23 billion, accounting for more than half of the company's total revenue.
🛡️ Newer cancer medicines like Breyanzi and Camzyos helped offset steep declines in older products facing generic competition.
⚠️ Analysts noted that Opdivo sales fell 5% to $2.15 billion, missing estimates due to wholesalers reducing inventory levels.
🔬 The company added another $163 million in revenue from Opdivo Qvantig, the subcutaneously injected version launched last year.
💡 Bristol Myers reaffirmed its 2026 outlook for revenue between $46.0 billion and $47.5 billion with earnings trending toward the higher end.
🤖 The CEO announced AI use in R&D will speed up drug molecule identification by 50% and cut clinical development times by 30%.
💸 Ongoing cost-cutting efforts have delivered $1 billion of planned savings, with a target to hit the full $2 billion by year-end.
📉 Analyst Trung Huynh highlighted mixed performance in growth drivers like Opdivo and Reblozyl as key considerations for future quarters.
📅 Analysts believe 2026 catalysts such as next-generation cancer drug approvals and late-stage study results will be critical.
Bullish Signals
Adjusted earnings hit $1.58/share, beating estimates.
Bristol Myers Squibb reported first-quarter adjusted earnings of $1.58 per share, significantly beating analyst expectations of $1.42.
Revenue reached $11.49 billion, surpassing the estimated target of approximately $10.9 billion.
Shares rose 4% following the strong quarterly performance driven by better-than-expected growth in key medicines.
Eliquis sales grew 16% year-over-year to $4.14 billion, with new prescription share now surpassing 75% of the market.
Growth from newer cancer medicines and the expansion of Opdivo Qvantig helped offset declines in older products facing generic competition.
Sales from the growth portfolio increased 12% to $6.23 billion, accounting for more than half of total revenue.
The company reaffirmed its 2026 revenue guidance of $46.0 billion to $47.5 billion with results trending toward the higher end.
CEO Chris Boerner highlighted that AI usage will accelerate drug molecule identification by about 50% and reduce clinical development cycle times by 30%.
Cost-cutting efforts have delivered $1 billion in savings, with the full $2 billion target on track to be met by the end of 2026.
Ongoing investment in newer medicines and dividend growth is supported by current cost-saving initiatives.
Risk Factors
Revenue growth from older products is being offset by steep declines in key legacy medicines due to generic competition, such as Revlimid.
Sales of the original formulation of Opdivo dropped 5% to $2.15 billion, missing analyst estimates of $2.33 billion due to wholesalers reducing inventory levels.
Finance chief David Elkins expressed uncertainty about whether inventory levels will normalize over the balance of the year regarding Opdivo sales.
Analyst Trung Huynh warned that the beat was outweighed by mixed performance in some growth drivers, specifically noting declines for cancer drug Opdivo and anemia treatment Reblozyl.
The company's reliance on newer medicines has increased, with the growth portfolio accounting for more than half of total revenue at $6.23 billion.
Future stock performance may depend less on 2026 quarters and more on late-stage study results from milvexian and Cobenfy in H2 2026, introducing execution risk.
Bristol-Myers Squibb (NYSE: BMY) has garnered renewed attention following the release of positive Phase 3 data for its drug Camzyos in adolescents with obstructive hypertrophic cardiomyopathy and the announcement of a multi-year collaboration focused on T-cell engager therapeutics with Oxford BioTherapeutics. The company is currently trading at a share price of US$59.47, which corresponds to a nine-day return of 6.46% and an 11.24% year-to-date gain, while the one-year total shareholder return stands at 23.74%. Analysts and the platform analyzing the stock suggest that these positive developments in late-stage pipeline news are driving momentum for the healthcare giant.
Financially, Bristol-Myers Squibb reported full-year 2024 revenues of $48.3 billion, representing a 7% increase from 2023 figures. Despite a GAAP loss per share of $(4.41) compared to $3.86 in 2023, the company demonstrated resilience with non-GAAP earnings per share of $1.15 and significant growth in its newer product portfolio, which generated $22.6 billion in revenue, a 17% increase from the previous year. The analysis indicates that the current market price of US$59.47 trades at a discount to both the US$63.04 average analyst target and a calculated fair value narrative of US$65.00, leading analysts to classify the stock as undervalued with a value score of 5.
The positive valuation outlook relies heavily on the sustained momentum of its growing portfolio of newer products alongside optimistic margin assumptions. However, there are significant risks that could challenge this bullish narrative, specifically if growth portfolio momentum slows down or if projected cost savings and earnings guidance fail to translate into more stable reported profitability. The article notes that investor opinions remain split between concerns over these potential headwinds and optimism regarding the upcoming rewards from recent data releases and partnerships, resulting in a fair value assessment that suggests the gap between the current price and the US$65.00 fair value is hard to ignore.
📈 BMY shares gained 11% YTD with 23.74% total annualized return so far.
💰 Stock trades at a 9% discount to estimated fair value of US$65.00.
📊 Full-year revenue grew 7% to $48.3B, led by growth portfolio surge.
⚠️ GAAP loss widened due to restructuring costs despite strong new product sales.
💡 Investment focuses on future margins from newer therapies rather than legacy earnings.
📈 Bristol-Myers Squibb (BMY) shares closed at US$59.47, reflecting positive momentum following recent data releases and partnerships.
💖 The company released positive Phase 3 data for its drug Camzyos in adolescents with obstructive hypertrophic cardiomyopathy.
🤝 BMY announced a new multi-year collaboration to develop T-cell engager therapeutics with Oxford BioTherapeutics.
📊 Year-to-date share price return stands at 11.24%, contributing to an annualized total shareholder return of 23.74%.
💰 At the current share price, BMY trades at a discount to its average analyst target price of US$63.04.
📉 Full-year 2024 revenues reached $48.3 billion, representing a 7% increase compared to 2023.
❌ GAAP loss per share widened to $(4.41) in 2024 from earnings of $3.86 in 2023 due to investment and restructuring costs.
📈 Non-GAAP EPS decreased significantly to $1.15, down from $7.51 in the previous year.
🌱 Growth portfolio revenues jumped 17% year-over-year to $22.6 billion, indicating strong performance of newer products.
💡 Simply Wall St calculates a fair value of US$65.00 for BMY, suggesting the stock is currently undervalued by roughly 9%.
⚠️ Investors face risks if growth portfolio momentum slows or if cost savings fail to stabilize reported profitability.
🛡️ Simply Wall St highlights that the company holds a "fair value" narrative despite current GAAP losses driven by strategic investments.
🔄 The investment thesis relies on newer products driving future margins and valuation rather than legacy oncology earnings alone.
Bullish Signals
Phase 3 Camzyos data in adolescents strengthens pipeline.
New T-cell engager collaboration adds oncology potential.
Growth portfolio revenues reached $22.6 billion, up 17% from 2023.
Total shareholder return of 23.74% reflects strong momentum.
Stock trades at discount to $65 fair value target.
Full-year 2024 revenues reached $48.3 billion, up 7% from 2023.
Non-GAAP EPS for 2024 was $1.15 showing profitability.
Analysts suggest stock undervalued at current price of $59.47.
Focus on newer products supports long-term revenue growth.
GAAP loss widened to $(4.41) from 2023 $3.86 earnings.
Non-GAAP EPS fell from $7.51 in 2023 to $1.15.
Stock trades at US$59.47 versus US$65.00 fair value target.
Valuation depends on future growth which could easily reverse.
Profitability risks if cost savings fail to translate efficiently.
Bullish Signals
Bristol-Myers Squibb announced positive Phase 3 data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy, strengthening its pipeline.
A new multi-year T-cell engager collaboration with Oxford BioTherapeutics adds significant oncology potential to the company's portfolio.
Growth Portfolio Revenues reached $22.6 billion, representing a robust 17% increase from 2023, highlighting strong performance of newer products.
Total shareholder return over the past year was 23.74%, demonstrating building momentum around recent Camzyos data and oncology collaborations.
The stock currently trades at a modest discount to analyst targets with a fair value assessment of $65.00 versus the current price of $59.47, suggesting potential upside.
Full-Year 2024 Total Revenues were $48.3 billion, marking a 7% increase from 2023.
Non-GAAP EPS for 2024 was $1.15, indicating profitability metrics despite GAAP loss.
Analyst consensus suggests the stock is undervalued with a calculated fair value of $65.00.
The company's focus on a growing set of newer products supports long-term revenue growth.
Recent positive catalysts including Camzyos data and new collaborations have strengthened investor sentiment.
Risk Factors
GAAP loss per share widened significantly to $(4.41) from earnings of $3.86 in 2023, indicating deteriorating core profitability despite overall revenue growth.
Non-GAAP EPS dropped substantially from $7.51 in 2023 to just $1.15, suggesting a potential mismatch between current valuation assumptions and recent earnings performance.
The company is trading at a share price of US$59.47 against a fair value target of US$65.00, but the gap relies on future growth momentum that could easily reverse if newer product sales slow down.
Analyst consensus targets the stock at US$63.04, meaning current investor sentiment may already be pricing in some positive developments from recent clinical trial data and collaborations.
The valuation narrative depends heavily on cost savings successfully translating into stable reported profitability, creating a key risk if management fails to deliver on efficiency gains.
Bristol-Myers Squibb shares gained 10.2% year to date, significantly outperforming the biotechnology industry's 1.6% growth and the broader S&P 500 index as of late April. This sustained rally has helped restore investor confidence in the company's ability to navigate generic competition eroding revenues from legacy products. The positive momentum is driven by a robust growth portfolio, which accounted for approximately 55% of total revenues in 2025, anchored by key drugs such as Opdivo, Orencia, Reblozyl, Camzyos, Breyanzi, and the newer schizophrenia treatment Cobenfy.
The legacy portfolio continues to face structural headwinds from generic competition, resulting in a 15% revenue decline in 2025, with key affected products including Revlimid, Pomalyst, Sprycel, and Abraxane. This segment generated 45% of total 2025 revenues, totaling $48.2 billion, though demand for Eliquis remains solid. Management expects a 12-16% decline in the legacy portfolio in 2026 due to ongoing patent expiries and pricing headwinds, while Eliquis is forecast to grow 10-15%. Additional policy-driven pressure will include supplying Eliquis at no cost to Medicaid under a new agreement effective January 1, 2026, along with significant discounts on other products like Sotyktu and Orencia SC for eligible cash-paying patients.
Bristol-Myers Squibb's growth trajectory is further supported by a deep pipeline and recent strategic acquisitions. The company expects top-line registrational data in 2026 for six candidates, including milvexian and admilparant. Recent positive interim results from the late-stage SUCCESSOR-2 study for mezigdomide marked an important milestone for its next-generation CELMoD program, reinforcing confidence in its targeted protein degradation platform. Additionally, the recent acquisition of Orbital Therapeutics added OTX-201, a preclinical RNA CAR-T therapy, and in 2025, the company partnered with BioNTech to co-develop pumitamig for solid tumors, highlighting ongoing efforts to expand its therapeutic options despite market challenges.
💰 Eliquis generated $48.2B in 2025 revenue despite generic pressures.
⚡ Growth Portfolio contributed 55% of total revenues driven by oncology drugs.
🧬 Pipeline includes six candidates expected to report data in 2026.
🤝 Legacy portfolio guides 12-16% revenue decline for 2026 due to expiries.
📈 BMY shares have gained 10.2% year-to-date, significantly outperforming the industry's 1.6% growth and the S&P 500.
💊 The Growth Portfolio comprised about 55% of total revenues in 2025, driven largely by the immuno-oncology franchise.
⚡ Opdivo remains the top revenue contributor, supported by label expansions and share gains in non-small cell lung cancer.
🔬 Opdualag has become a standard-of-care option for first-line melanoma in the United States with robust growth.
💰 Reblozyl partnered with Merck & Co has surpassed $2 billion in annualized sales due to strong adoption in anemia treatments.
🧪 Breyanzi crossed a $1 billion run rate in large B-cell lymphoma, with further growth anticipated for 2026.
⚖️ Cobenfy generated $155 million in 2025 sales as the first novel pharmacological approach to schizophrenia in decades.
📉 The legacy portfolio faced a 15% revenue decline in 2025 due to generic competition affecting products like Revlimid and Pomalyst.
💵 Eliquis, co-developed with Pfizer, generated 45% of total 2025 revenues ($48.2 billion) despite generic pressures.
📅 Management guides for a 12-16% decline in the legacy portfolio for 2026 due to patent expiries and pricing headwinds.
🛑 Eliquis will be supplied at no cost to Medicaid starting Jan. 1, 2026, under a new U.S. agreement affecting net pricing.
🧬 BMY's pipeline includes six candidates expected to report top-line registrational data in 2026 for various indications.
✨ The company recently reported positive interim results from the late-stage SUCCESSOR-2 study for mezigdomide in multiple myeloma.
🤝 The acquisition of Orbital Therapeutics adds OTX-201, a preclinical RNA CAR-T therapy, to expand the autoimmune disease portfolio.
Bullish Signals
Shares gained 10.2% YTD vs 1.6% industry growth.
Growth Portfolio represents 55% of 2025 revenues.
Opdivo remains leading revenue contributor.
Opdualag delivering robust US growth in melanoma.
Reblozyl surpassed $2B in annualized sales.
Breyanzi crossed $1B run rate.
Cobenfy generated $155M in 2025 sales.
Six candidates expected to report 2026 data.
SUCCESSOR-2 study shows positive interim results.
Risk Factors
Legacy portfolio faces 15% revenue decline in 2025 from generic competition.
Management projects 12-16% additional revenue decline for legacy segment in 2026.
Eliquis supply at no cost to Medicaid effective Jan. 1, 2026 pressures margins.
Growth products face discounts to cash patients impacting revenue.
Eliquis growth only partially offsets legacy segment declines.
Shares up 10.2% vs 1.6% industry growth signals overvaluation risk.
Generic erosion creates persistent structural headwinds for core revenues.
Bullish Signals
Bristol Myers Squibb shares have gained 10.2% year to date, significantly outperforming the industry's growth of 1.6% and both the sector and S&P 500.
The company's Growth Portfolio accounts for approximately 55% of total revenues in 2025, anchored by key drugs like Opdivo, which remains the leading revenue contributor due to continued label expansions and sustained share gains in first-line non-small cell lung cancer.
Opdualag continues to deliver robust growth in the United States, becoming a standard-of-care option in first-line melanoma.
Reblozyl has surpassed $2 billion in annualized sales with strong adoption across both first- and second-line MDS-associated anemia.
Breyanzi has crossed a $1 billion run rate, reflecting solid uptake in large B-cell lymphoma with further growth anticipated in 2026.
Cobenfy generated $155 million in 2025 sales as access expands and adoption deepens, representing a potentially meaningful long-term growth driver for schizophrenia.
BMY expects to report top-line registrational data for six candidates in 2026 across various indications including atrial fibrillation, idiopathic pulmonary fibrosis, and multiple myeloma.
The company recently announced positive interim results from the late-stage SUCCESSOR-2 study for mezigdomide, marking an important milestone for its next-generation CELMoD program.
Risk Factors
The legacy portfolio faces a projected 15% revenue decline in 2025 due to generic competition affecting key products like Revlimid, Pomalyst, Sprycel, and Abraxane.
Management guides for an additional 12-16% revenue decline in the legacy portfolio for 2026, driven by ongoing patent expiries and pricing headwinds.
Policy-driven changes introduce incremental pressure on net pricing and margins, with Eliquis to be supplied at no cost to Medicaid under a new U.S. agreement effective Jan. 1, 2026.
Several growth products, including Sotyktu, Zeposia, and Orencia SC, will face significant discounts to eligible cash-paying patients, potentially impacting revenue growth from these assets.
While Eliquis is expected to deliver 10-15% growth, this is noted as only partially mitigating the overall legacy segment decline in coming years.
The article acknowledges that Bristol Myers' shares have gained 10.2% year-to-date compared to the industry's 1.6% growth, which may signal overvaluation relative to broader sector performance.
Generic erosion of legacy products remains a structural headwind that requires continued navigation, suggesting persistent challenges in core revenue streams.
Bristol Myers Squibb announced on Monday a new multi-year cancer immunotherapy partnership with Oxford BioTherapeutics, focusing on developing novel T cell engager therapies for solid tumors. The collaboration is structured as an R&D alliance designed to expand the company's oncology pipeline by leveraging Oxford BioTherapeutics' proprietary platform to target areas where treatment options are currently limited compared to blood cancers. This deal adds another layer to Bristol Myers Squibb's established focus on oncology and immunology, representing continued interest in next-generation immunotherapies that could potentially broaden the company's oncology reach if the programs progress well.
For investors tracking the New York Stock Exchange-listed NYSE:BMY stock, key questions center on how this partnership fits alongside existing cancer programs and its potential impact on Bristol Myers Squibb's competitive position in solid tumor treatments over the long term. The collaboration highlights ongoing investment in research programs that could shape the company’s oncology portfolio, potentially influencing future R&D resource allocation and pipeline decisions. Analysts have set a price target range of US$40 to US$75 for the stock, with the current P/E ratio noted at 17.2.
Simply Wall St notes that Bristol Myers Squibb shares are currently trading at US$59.47, which is approximately 6% below the consensus analyst target of US$63.04 and roughly 51.3% below an internal fair value estimate. Recent market momentum has been slightly negative with a 30-day return decline of about 1.1%. While the Oxford BioTherapeutics deal adds a significant asset to the portfolio, the analysis warns that high debt levels and large one-off items in financial results remain key risks alongside long-term drug development partnerships. The company maintains a focus on oncology and immunology, but investors are advised to monitor R&D spend, trial updates, and milestone disclosures from this alliance in relation to current valuation metrics.
🤝 BMY partners with Oxford BioTherapeutics to develop T cell engager therapies for solid tumors.
📉 Stock trades at $59.47, roughly 6% below analyst consensus target and 51% under Simply Wall St valuation.
⚠️ Key risks include high debt levels, large one-off items, and negative recent momentum with slight declines.
🤝 Bristol Myers Squibb (BMY) announced a new multi-year cancer immunotherapy partnership with Oxford BioTherapeutics.
🎯 The collaboration focuses on developing novel T cell engager therapies specifically for solid tumors using Oxford's proprietary platform.
🧬 T cell engagers represent one approach to target solid tumors, an area where treatment options are often limited compared to blood cancers.
📈 This partnership aims to expand Bristol Myers Squibb's oncology pipeline and add to its research programs in cancer immunotherapy.
💡 Investors will be monitoring how this tie-up fits with existing cancer programs and impacts the company's competitive position long-term.
⚖️ The current stock price of US$59.47 is about 6% below the consensus analyst target of US$63.04.
📉 Shares are trading roughly 51.3% below Simply Wall St's internal fair value estimate.
📉 Recent momentum shows a 30-day return of an approximately 1.1% decline, indicating slightly negative market sentiment.
💰 Bristol Myers Squibb currently trades at a P/E ratio of 17.2 with an analyst price target range of US$40 to US$75.
⚠️ Key risks include high debt levels and the presence of large one-off items in recent financial results.
🔬 Successful progression of this T cell engager deal could broaden Bristol Myers Squibb's reach into solid tumor treatments.
📊 Analysts will watch R&D spend and trial updates to evaluate if they align with current valuation metrics.
⚠️ Investors should consider the long-term nature of drug development partnerships alongside financial risks before making decisions.
Bullish Signals
New multi-year cancer immunotherapy partnership announced with Oxford BioTherapeutics.
Focus on developing novel T cell engager therapies for solid tumors.
Adds solid tumor program to broaden Bristol-Myers Squibb oncology reach.
Shares trade 51.3% below internal fair value estimate, indicating upside.
Analysts consensus price target $63.04 vs current price about $59.47.
P/E ratio of 17.2 with analyst targets ranging from $40 to $75.
Partnership shows interest in next generation immunotherapies and R&D allocation.
Risk Factors
Shares trading 6% below consensus target of $63.04 at $59.47.
Stock down 51.3% from Simply Wall St fair value model.
Negative momentum over last 30 days with 1.1% decline.
High debt levels cited as key risk factor.
Analyst targets range $40-$75 indicating valuation uncertainty.
Bullish Signals
Bristol Myers Squibb announced a new multi-year cancer immunotherapy partnership with Oxford BioTherapeutics, expanding its oncology pipeline.
The collaboration focuses on developing novel T cell engager therapies for solid tumors using Oxford BioTherapeutics' proprietary platform.
This deal adds another solid tumor program that could broaden Bristol-Myers Squibb's oncology reach if it progresses well.
Shares are trading roughly 51.3% below an internal fair value estimate, indicating potential upside.
Analysts have set a consensus price target of US$63.04 compared to the current price of about US$59.47.
The company operates with a P/E ratio of 17.2 and has analyst price targets ranging from US$40 to US$75, suggesting room for growth.
The partnership highlights continued interest in next generation immunotherapies and may influence how the company allocates R&D resources.
Risk Factors
Shares are trading 6% below the consensus analyst target price of US$63.04, currently at US$59.47.
Simply Wall St's internal fair value model indicates the stock is trading roughly 51.3% below its calculated fair value.
The stock has experienced negative momentum over the last 30 days with a return of about 1.1% decline.
The company carries high debt levels which is cited as a key risk factor alongside large one-off items in financial results.
Analyst price target ranges widely from US$40 to US$75, suggesting significant uncertainty around the stock's valuation.
Rovi has completed the acquisition of a pharmaceutical manufacturing plant located in Phoenix, Arizona, following the execution of an Asset Purchase Agreement with Bristol Myers Squibb (BMS). The transaction was carried out through Rovi's subsidiary, ROIS Phoenix Inc., and involved the purchase of the facility along with associated assets and liabilities. This deal has been formally notified to Spain's National Securities Market Commission (CNMV), confirming its finalization after meeting all customary closing conditions and ensuring no significant adverse changes had occurred since the initial signing.
As part of this strategic transaction, Rovi has established a Toll Manufacturing Agreement with Bristol Myers Squibb. Under the terms of this agreement, ROIS Phoenix is set to continue manufacturing pharmaceutical products for BMS at the acquired plant. The arrangement includes provisions for the necessary staffing to ensure the facility operates effectively under the new ownership structure. This move allows Rovi to integrate the plant into its operations while maintaining a key manufacturing partnership with a major pharmaceutical client like Bristol Myers Squibb, leveraging the existing operational framework already in place.
🏭 Rovi finalized acquisition of Phoenix pharmaceutical manufacturing plant.
⚖ Transaction closed with CNMV notification and no adverse changes.
🤝 Deal includes Asset Purchase Agreement and Toll Manufacturing for BMS.
🏭 Rovi has finalized the acquisition of a pharmaceutical manufacturing plant in Phoenix, Arizona.
🤝 The deal involved an Asset Purchase Agreement executed between ROIS Phoenix Inc. and Bristol Myers Squibb (BMS).
⚖️ The company notified the National Securities Market Commission (CNMV) of the completed transaction.
✅ Closing occurred after customary conditions were met with no significant adverse changes.
🧪 As part of the agreement, Rovi entered into a Toll Manufacturing Agreement to continue production for BMS.
👥 The plant will operate with necessary staff already in place or hired under communicated conditions.
💼 The transaction includes related assets and liabilities associated with the manufacturing facility.
Bullish Signals
Rovi completed $895M BMS plant acquisition in Phoenix.
Secured toll manufacturing agreement for ongoing revenue.
Risk Factors
Article contains no negative metrics or risks.
No declining metrics, competitive threats, or regulatory concerns.
Completion conditions met with no significant adverse changes.
Transaction completion implies no current downside catalysts.
Bullish Signals
Rovi successfully completed the acquisition of a pharmaceutical manufacturing plant in Phoenix, Arizona from Bristol Myers Squibb (BMS), marking a significant expansion in its manufacturing capabilities.
The company confirmed it has secured a Toll Manufacturing Agreement with BMS to continue operations at the newly acquired plant, ensuring ongoing revenue streams and utilization of the facility.
Risk Factors
This is a business news article about an acquisition completion - it's fundamentally positive/neutral news.
The content doesn't mention any downsides, risks, concerns, or negative metrics.
There are no declining metrics mentioned.
No competitive threats.
No regulatory concerns expressed.
No downside catalysts listed.
The completion "took place once the customary closing conditions for this type of transaction had been met and no significant adverse changes had occurred since its signing" - this implies uncertainty about whether there might have been such changes (though it says none did).
Jim Cramer reviewed Bristol-Myers Squibb (NYSE:BMY) during a segment analyzing 16 stocks suitable for a market environment characterized by higher energy costs and economic uncertainty. Cramer highlighted that he owns the pharmaceutical company’s stock for the Charitable Trust, noting its significant performance over the past year. The stock experienced a substantial rally from November through February but recently stalled; however, it has still risen quietly 28% since late October. Cramer expressed surprise at recent technical activity as the stock broke out above its 50-day moving average after pulling back in recent weeks, a move analyst Lang attributes to a healthy correction rather than a trend change.
Technical indicators and fundamentals continue to support Cramer’s bullish outlook on BMY. He pointed out that the Chaikin Money Flow remains strong, mirroring the behavior he observed with Merck, suggesting these pullbacks present excellent buying opportunities. Currently trading at $58.94, Bristol-Myers offers a robust 4.3% dividend yield. Analyst Lang sees potential for the stock to advance between $66 and $70, positioning it as an ideal holding if the market faces a harsh economic slowdown. Its high yield provides income protection, while the underlying business develops and sells medicines for cancer, cardiovascular, immune, and neurological conditions with well-known products including Eliquis, Opdivo, and Orencia.
Despite acknowledging BMY's potential as an investment, the article contrasts it with emerging sectors like artificial intelligence. The author suggests that certain AI stocks may offer greater upside potential with less downside risk compared to traditional pharmaceutical giants. Furthermore, the content points to a separate free report focused on undervalued AI stocks that could benefit from Trump-era tariffs and the trend of onshoring, directing readers toward specific short-term investment opportunities in that space. The overall narrative positions BMY as a defensive stock for difficult economic times while simultaneously promoting higher-risk, high-reward AI alternatives for investors seeking aggressive growth.
📈 Jim Cramer recommends BMY as a top pick for his Charitable Trust.
💊 Eliquis and Opdivo are key products driving cancer and immune therapies.
💰 A 4.3% dividend yield offers protection against potential economic slowdowns.
🔍 Strong buying signals suggest the stock could reach $66–$70 soon.
⚖ Recent price drops are viewed as healthy corrections, not fundamental weakness.
📈 Jim Cramer recommends Bristol-Myers Squibb (BMY) as a top pick for the Charitable Trust he manages.
📉 The stock recently stalled after a strong 28% gain since late October but broke out above its 50-day moving average.
💰 BMY offers a solid 4.3% dividend yield, providing protection in a potential harsh economic slowdown.
🔬 The pharmaceutical company develops medicines for cancer, cardiovascular, immune, and neurological conditions.
💊 Key products include well-known drugs such as Eliquis, Opdivo, and Orencia.
📈 Analyst Lang sees the stock making a run to between $66 and $70 from its current level of $58.94.
🔍 Chaikin Money Flow metrics indicate that buying opportunities are strong despite recent pullbacks.
⚖️ Cramer views recent price drops as healthy corrections rather than signs of fundamental weakness.
🤝 The recommendation aligns with owning defensive stocks during economic uncertainty and higher energy costs.
❗ Insider Monkey notes that AI stocks may offer greater upside potential compared to BMY.
📰 Additional content links promote reports on short-term AI stocks and other high-performing equities.
Bristol-Myers Squibb (NYSE:BMY) is owned by the Charitable Trust, indicating strong institutional confidence in the stock.
The stock has already gained a quiet 28% since the end of October, demonstrating recent positive momentum.
Technical analysis shows the stock broke out above the 50-day moving average, signaling a potential continuation of the uptrend.
Chaikin Money Flow remains strong, suggesting sustained buying pressure into the current pullback.
The company offers a strong 4.3% dividend yield, providing attractive income protection even if economic conditions slow down.
Analyst Lang sees upside potential with price targets ranging from $66 to $70 against the current price of $58.94.
Bristol-Myers develops and sells key medicines for cancer, cardiovascular, immune, and neurological conditions, including well-known drugs like Eliquis, Opdivo, and Orencia.
Risk Factors
The stock has recently stalled after a massive run from November through February, indicating potential weakness following its prior rally.
Despite being up 28% since the end of October, Bristol-Myers Squibb (NYSE:BMY) is currently trading at $58.94 with a target range of $66 to $70 by Lang, which represents modest upside potential.
Bristol-Myers Squibb (BMY) shares recently closed at $59.43, displaying mixed returns across various short-term and long-term periods including a 1-day gain of 0.83%, a 7-day rise of 2.27%, and a 90-day increase of 8.77%. However, the longer-term outlook presents a more tempered picture with a year-to-date return of 11.17% and a one-year total shareholder return of 6.00%, while the five-year total shareholder return stands at 14.28%. The current valuation analysis suggests the stock is trading at an intrinsic value estimate implying a discount of approximately 51%, leading to a fair value estimate of $65.00 according to the featured narrative, which characterizes the shares as modestly undervalued.
Financial highlights for Full-Year 2024 reveal that total revenues reached $48.3 billion, marking a 7% increase from 2023. Despite this revenue growth, GAAP losses widened significantly, with loss per share reporting at $(4.41) compared to earnings of $3.86 in 2023. Conversely, non-GAAP EPS was reported at $1.15, down from $7.51 in the prior year. The growth portfolio demonstrated robust performance with revenues of $22.6 billion, representing a 17% increase, which underpins the narrative's focus on future earnings power and margin recovery assumptions rather than headline GAAP figures.
Valuation metrics indicate that BMY currently trades at a P/E ratio of 17.2x, positioning it slightly above the US pharmaceuticals average of 16.9x but below both the peer average of 19.8x and a fair ratio of 24.2x. The article highlights potential risks such as a possible decline from 2024 revenue guidance to 2025 projections and execution challenges regarding the planned US$2 billion cost savings program. Investors are encouraged to weigh these risks against rewards including the company's resilience, growth portfolio strength, and the possibility of market re-rating, though Simply Wall St clarizes that this analysis is general in nature based on historical data and forecasts rather than specific financial advice.
On March 27, 2026, Bristol-Myers Squibb (NYSE:BMY) announced a strategic collaboration with the National Council for Mental Wellbeing aimed at bridging critical gaps in schizophrenia care through evidence-based models and expanded community access. The initiative will focus on improving engagement, retention, and clinical outcomes for individuals living with schizophrenia by strengthening care team integration and promoting recovery-oriented services in community-based settings.
A central component of this partnership is the publication of a white paper titled "Advancing Person-Centered Care: Peer Support in Schizophrenia Care in Certified Community Behavioral Health Clinics," which outlines the value of peer support workers drawn from individuals with lived experience in mental health or substance use challenges. The document reviews the peer support landscape based on peer-reviewed research and insights from Certified Community Behavioral Health Clinics (CCBHCs), highlighting that defining roles, embedding peers early in care, providing structured supervision, and investing in training can significantly improve service utilization. It further offers recommendations to policymakers regarding funding expansion, streamlined referrals, and sustainable reimbursement policies.
Beyond the white paper, the collaboration has launched two pilot programs expected to share initial updates in early 2027: one designed to expand peer support services and another investigating the use of predictive analytics models to enhance continuity of care. Additionally, themes of peer support and predictive analytics will be featured at NatCon, the annual conference for National Council members scheduled for April 27, with a specific breakout session titled "Trust, Connection, and Continuity: The Opportunity of Peer Support in Care for People with SMI." Leaders from both organizations emphasized that this partnership aims to foster a person-centered ecosystem that values empathy, trust, and hope, addressing the reality that fewer than half of the one-in-five adults who experience mental illness each year currently receive the care they need.
🤝 BMY and the National Council partner to improve schizophrenia care via evidence-based models.
📄 A new white paper highlights how peer support workers build trust and hope for patients.
🚀 Two pilot programs will test expanded services and predictive analytics with updates by 2027.
🤝 Bristol-Myers Squibb (BMY) and the National Council for Mental Wellbeing announced a new collaboration to improve schizophrenia care through evidence-based models.
📄 The partnership launches with the publication of a white paper titled "Advancing Person-Centered Care: Peer Support in Schizophrenia Care in Certified Community Behavioral Health Clinics."
👥 The white paper highlights the critical role of peer support workers who have lived experience to build trust and promote hope for patients.
📊 It reviews peer-reviewed research and CCBHC case studies showing that structured training and early embedding of peers improve service utilization.
🏛️ Recommendations in the document include policy changes for expanded funding, streamlined referrals, and sustainable reimbursement models.
👨💼 Chuck Ingoglia, National Council CEO, emphasized accelerating innovation through effective industry-community collaboration to fill care coordination gaps.
🏥 Andrew Whitehead from BMS noted that while clinical progress exists, barriers prevent many patients from achieving stability and connection.
🔬 The initiative will launch two pilot programs: one expanding peer support services and another applying predictive analytics for continuity of care.
📅 Both pilot programs are expected to share initial updates in early 2027.
🎤 Speaker Nicole Tierney, a certified recovery specialist, praised the white paper as evidence-based guidance for clinics to enhance patient experiences.
🗣️ The collaboration will feature a breakout session at NatCon on April 27 regarding peer support opportunities for Serious Mental Illness care.
🏥 Certified Community Behavioral Health Clinics (CCBHCs) serve as key partners providing crisis care, therapy, and social services to patients.
Bullish Signals
Bristol-Myers Squibb partners with National Council for Mental Wellbeing.
White paper highlights peer support value for patient retention.
Pilot programs expand services and predictive analytics for continuity of care.
Partnership strengthens care team integration and access to recovery services.
Data shows embedding peers improves service utilization in CCBHCs.
Recommendations target policy changes for sustainable nationwide peer support.
Risk Factors
Updates delayed until early 2027; immediate impact uncertain.
Underhalf adults seek care; demand may overwhelm efforts.
Funding faces barriers from reimbursement limits and resource constraints.
Pilots risk data privacy issues and unproven algorithm accuracy.
CCBHC capacity limited by staffing shortages and sustainability fears.
Bullish Signals
Bristol-Myers Squibb (NYSE:BMY) announced a strategic collaboration with the National Council for Mental Wellbeing to advance evidence-based care models for schizophrenia, signaling strong commitment to population health initiatives.
The partnership's first initiative is the publication of a white paper demonstrating the value of peer support programs to improve patient engagement, retention, and clinical outcomes in community-based settings.
Two new pilot programs are underway: one expanding peer support services and another utilizing predictive analytics to enhance continuity of care for individuals with schizophrenia, with initial updates expected in early 2027.
The collaboration aims to strengthen care team integration and expand access to recovery-oriented services, addressing significant gaps in care coordination and ongoing support across communities.
Evidence from Certified Community Behavioral Health Clinics (CCBHCs) shows that defining peer roles, embedding peers early in care, and investing in training can significantly improve service utilization.
The white paper provides actionable recommendations for policymakers to expand program funding and strengthen reimbursement policies to provide sustainable, scalable peer support services nationwide.
Risk Factors
The collaboration is limited to pilot programs with initial updates expected no sooner than early 2027, leaving immediate clinical impact uncertain.
Less than half of adults who experience mental illness each year receive the care they need, indicating a significant unmet demand that BMS's initiatives may struggle to fully address without major structural changes.
The collaboration relies on expanding access and funding for peer support services, which faces potential barriers from reimbursement policy limitations and healthcare resource constraints.
Predictive analytics pilots introduce operational risks related to data privacy, algorithmic accuracy, and integration with existing care infrastructure that have not yet been proven.
The initiative depends heavily on community-based Certified Community Behavioral Health Clinics (CCBHCs) whose capacity may be limited by staffing shortages and sustainability concerns in the behavioral health sector.
Bristol Myers Squibb (BMY) received FDA approval on Friday for its oral medication, Sotyktu, to treat active psoriatic arthritis in adults. The decision was based on late-stage trial data demonstrating superior disease control compared to placebo. The drug works by selectively targeting tyrosine kinase 2, a pathway involved in immune-driven inflammation.
The approval follows two global Phase 3 studies, POETYK PsA-1 and POETYK PsA-2, where patients took either a daily 6-milligram tablet or placebo during the controlled portion of the trials. Using American College of Rheumatology response criteria, investigators found that by Week 16, approximately 54% of patients on Sotyktu achieved an ACR20 response in both studies, compared to 34% and 39% for placebo groups respectively. This difference was statistically significant. Additional measures showed meaningful gains in minimal disease activity scores, indicating broader relief across joints, skin, and patient-reported pain. About one-quarter of treated patients achieved an ACR50 response.
"This announcement marks the introduction of a new, differentiated option to treat adults with active psoriatic arthritis," said Al Reba, senior vice president of cardiovascular and immunology commercialization at Bristol Myers Squibb. The FDA had previously approved Sotyktu in 2022 for moderate-to-severe plaque psoriasis, so this clearance expands its indicated use to include the joint disease, which affects up to 30% of people with psoriasis. Common side effects observed included respiratory infections, mouth ulcers, acne, and higher muscle enzyme levels, with warnings issued regarding infection risk, viral reactivation, and possible malignancies requiring tuberculosis screening before treatment begins. Dr. Philip J. Mease noted that patients showed better quality-of-life scores during the trials, confirming the drug's clinical impact.
The summary above contains relevant details about the drug, trial results, quotes from company executives, side effects, and historical context for FDA approval. However, it does not contain any information about Bristol Myers Squibb (BMY) stock price, earnings reports, or financial metrics. It is possible that this article is from a news aggregator website that includes unrelated content such as advertisements, trending tickers, and other companies like Fire-Safe Energy Storage Company and AI companies mentioned in the text. Despite these distractions, the main focus of the article remains on BMY's Sotyktu drug and its FDA approval for psoriatic arthritis. Therefore, this article is worth keeping for its relevance to Bristol Myers Squibb's pipeline development and commercial progress.
🏭 FDA approved Sotyktu for active psoriatic arthritis in adults.
📉 Drug shows superior efficacy, achieving a 54% response rate at Week 16.
⚠ Safety profile matches earlier studies but requires TB screening and infection monitoring.
🏭 Bristol Myers Squibb has received U.S. FDA approval for its oral drug Sotyktu to treat adults with active psoriatic arthritis.
💊 The drug works by selectively targeting tyrosine kinase 2, a specific pathway involved in immune-driven inflammation.
📋 Approval was granted after reviewing late-stage trial data showing superior disease control compared to placebo.
🌍 Researchers conducted two global Phase 3 studies (POETYK PsA-1 and POETYK PsA-2) testing a daily 6-milligram tablet versus placebo.
📉 By Week 16, approximately 54% of patients on Sotyktu achieved an ACR20 response, compared to 34% and 39% in the placebo groups.
🩺 Other positive metrics included meaningful gains in minimal disease activity scores and improvements in patient-reported pain.
💼 Al Reba of Bristol Myers Squibb stated this marks a new option for treating both skin and joint symptoms of psoriatic disease.
😊 Dr. Philip J. Mease noted that patients showed better quality-of-life scores during the clinical trials.
⚠️ The safety profile is similar to earlier psoriasis studies, with common side effects including respiratory infections, mouth ulcers, acne, and elevated muscle enzymes.
🦠 Labels include warnings regarding infection risk, viral reactivation, potential malignancies, and a requirement for TB screening before treatment.
💾 Sotyktu was previously FDA approved in 2022 for moderate-to-severe plaque psoriasis before this new clearance for psoriatic arthritis.
📊 Psoriatic arthritis affects up to 30% of people with psoriasis, involving chronic inflammation of joints, tendons, and skin.
Bullish Signals
FDA approved Sotyktu for active psoriatic arthritis.
Sotyktu (BMS) showed 54% ACR20 response vs 34-39% placebo.
Drug provides relief across minimal disease activity and pain scores.
Sotyktu now treats psoriasis and expanded psoriatic arthritis use.
FDA approval confirms Sotyktu as a differentiated treatment option.
Risk Factors
Significant infection risks and malignancy warnings require strict monitoring.
Tuberculosis screening creates a regulatory hurdle and added burden.
Common side effects like mouth ulcers may impact patient adherence.
New indication limited to 30% of psoriasis patients restricts growth.
Modest efficacy: only 25% achieved ACR50 response in Phase 3.
Bullish Signals
Bristol Myers Squibb won U.S. FDA approval for its oral drug Sotyktu to treat adults with active psoriatic arthritis, marking a significant milestone in the drug's development.
Late-stage trial data demonstrated that Sotyktu provides better disease control than placebo, with 54% of patients achieving an ACR20 response compared to only 34% and 39% on placebo in the two global Phase 3 studies.
The drug showed meaningful gains across multiple measures, including minimal disease activity scores and patient-reported pain, indicating broader relief for joints and skin.
Sotyktu confirms its established role as a differentiated treatment option, having previously received FDA approval in 2022 for moderate-to-severe plaque psoriasis and now expanding its indicated use.
Senior vice president Al Reba stated the approval is a key milestone as the company continues to explore the drug's development for other diseases with limited or no current treatment options.
Risk Factors
Despite the approval, Sotyktu carries significant safety warnings including risks of infection, viral reactivation, and possible malignancies.
Physicians must screen patients for tuberculosis before starting treatment, indicating a notable regulatory hurdle and monitoring burden.
Common side effects such as respiratory infections, mouth ulcers, acne, and higher muscle enzyme levels could impact patient adherence and tolerability.
The new indication expands the drug from plaque psoriasis to psoriatic arthritis, which only affects up to 30% of psoriasis patients, limiting the immediate market expansion.
While Phase 3 data showed statistically significant benefits over placebo, only about one-quarter of treated patients achieved an ACR50 response, suggesting moderate efficacy for some endpoints.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)